[{"id":"7fda6a16-7aec-4560-a322-7d0985c54708","acronym":"EXCLAIM-2","url":"https://clinicaltrials.gov/study/NCT04129502","created_at":"2021-01-18T20:10:25.140Z","updated_at":"2024-07-02T16:35:03.030Z","phase":"Phase 3","brief_title":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","source_id_and_acronym":"NCT04129502 - EXCLAIM-2","lead_sponsor":"Takeda","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Exkivity (mobocertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 354","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-17"},{"id":"00bd8728-3f59-46ec-9a86-63c1172937ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03807778","created_at":"2021-01-18T18:49:03.389Z","updated_at":"2024-07-02T16:35:14.426Z","phase":"Phase 1","brief_title":"A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03807778","lead_sponsor":"Takeda","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR A763_Y764insFQEA • EGFR exon 20 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR A763_Y764insFQEA • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Exkivity (mobocertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 02/04/2019","start_date":" 02/04/2019","primary_txt":" Primary completion: 11/08/2021","primary_completion_date":" 11/08/2021","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-15"},{"id":"24a9df1f-6dbc-4a16-8c54-13431c420129","acronym":"EXCLAIM","url":"https://clinicaltrials.gov/study/NCT02716116","created_at":"2021-01-17T17:11:37.814Z","updated_at":"2024-07-02T16:35:32.901Z","phase":"Phase 1/2","brief_title":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02716116 - EXCLAIM","lead_sponsor":"Takeda","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Exkivity (mobocertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 334","initiation":"Initiation: 06/16/2016","start_date":" 06/16/2016","primary_txt":" Primary completion: 03/28/2025","primary_completion_date":" 03/28/2025","study_txt":" Completion: 03/28/2025","study_completion_date":" 03/28/2025","last_update_posted":"2023-10-18"},{"id":"30ddda77-130f-43d7-b23a-1382d2388609","acronym":"MEANING-20","url":"https://clinicaltrials.gov/study/NCT05863819","created_at":"2023-05-18T14:04:51.588Z","updated_at":"2024-07-02T16:35:32.905Z","phase":"","brief_title":"A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)","source_id_and_acronym":"NCT05863819 - MEANING-20","lead_sponsor":"Takeda","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Exkivity (mobocertinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/30/2024","start_date":" 03/30/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2023-10-18"},{"id":"602ec6ff-69dc-4f90-b7f8-87f603b41356","acronym":"","url":"https://clinicaltrials.gov/study/NCT04535557","created_at":"2021-01-18T21:42:32.134Z","updated_at":"2024-07-02T16:36:03.161Z","phase":"","brief_title":"An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations","source_id_and_acronym":"NCT04535557","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Exkivity (mobocertinib)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-09-30"},{"id":"fcc799e4-4858-48cc-938f-7d17cf4c2458","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576208","created_at":"2021-01-18T21:50:46.943Z","updated_at":"2024-07-02T16:36:37.262Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788","source_id_and_acronym":"NCT04576208","lead_sponsor":"Takeda","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Exkivity (mobocertinib) • loperamide"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2020","start_date":" 11/30/2020","primary_txt":" Primary completion: 07/31/2022","primary_completion_date":" 07/31/2022","study_txt":" Completion: 07/31/2022","study_completion_date":" 07/31/2022","last_update_posted":"2020-12-17"}]